Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis

NANot yet recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
CancerPulmonary EmbolismThrombosis
Interventions
BIOLOGICAL

Thrombin Generation Assay (TGA)

Hemostasis is a complex process in which genetic or environmental conditions can cause shifts either towards pro-thrombotic states resulting in thrombosis, or towards pro-hemorrhagic states resulting in uncontrolled bleeding. Tests to assess a more global hemostatic profile, such as the TGA, have appeared as a more reliable alternative to assess the real hemostatic capacity of an individual. TGA is a global dynamic assay simultaneously and continuously measuring thrombin generation. It monitors the cleavage of a fluorigenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.

Trial Locations (4)

38043

CHU de Grenoble, Grenoble

42055

Chu St-Etienne, Saint-Etienne

63003

Chu Clermont-Ferrand, Clermont-Ferrand

Unknown

HCL, Lyon

Sponsors
All Listed Sponsors
collaborator

Diagnostica Stago

INDUSTRY

collaborator

LEO Pharma

INDUSTRY

collaborator

Ligue contre le cancer, France

OTHER

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT06386107 - Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis | Biotech Hunter | Biotech Hunter